

# Neil T Parkin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/394548/publications.pdf>

Version: 2024-02-01

12  
papers

628  
citations

933447  
10  
h-index

1199594  
12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1353  
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. <i>Lancet Infectious Diseases</i> , 2018, 18, 346-355.	9.1	290
2	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. <i>Viruses</i> , 2020, 12, 1006.	3.3	60
3	Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. <i>Scientific Reports</i> , 2020, 10, 1634.	3.3	45
4	Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact. <i>Journal of Infectious Diseases</i> , 2020, 221, 1584-1597.	4.0	40
5	Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations. <i>Viruses</i> , 2020, 12, 617.	3.3	40
6	Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus. <i>Journal of the International AIDS Society</i> , 2018, 21, e25193.	3.0	34
7	Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. <i>Viruses</i> , 2020, 12, 694.	3.3	34
8	Evaluation of In-house Genotyping Assay Performance Using Dried Blood Spot Specimens in the Global World Health Organization Laboratory Network. <i>Clinical Infectious Diseases</i> , 2012, 54, S273-S279.	5.8	28
9	Genotyping External Quality Assurance in the World Health Organization HIV Drug Resistance Laboratory Network During 2007–2010. <i>Clinical Infectious Diseases</i> , 2012, 54, S266-S272.	5.8	22
10	Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” Symposium. <i>Viruses</i> , 2020, 12, 586.	3.3	18
11	External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations. <i>Viruses</i> , 2020, 12, 556.	3.3	7
12	Application of a Sanger-Based External Quality Assurance Strategy for the Transition of HIV-1 Drug Resistance Assays to Next Generation Sequencing. <i>Viruses</i> , 2020, 12, 1456.	3.3	2